Repligen Corp.
- RGEN ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Waltham, MA
- 2,000 employees
- CIK 0000730272
Updated from SEC filings through
Top things to know
Executives
- Olivier Loeillot Chief Executive Officer 4, 2026-09-25
- Jason K. Garland CFO 4, 2026-09-28
- Violetta Hughes CHIEF ACCOUNTING OFFICER 4, 2026-09-02
- Brian Robb Douglass CHIEF PRODUCT OFFICER 4, 2026-05-08
- James Bylund Chief Operating Officer 4, 2026-03-23
- Ralf Kuriyel Senior VP, R&D 4, 2026-03-23
Repligen Corp is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Waltham, MA. It trades as RGEN on Nasdaq. Revenue was $738M in the fiscal year ending December 31, 2025, +16.4% from the year before. It reported about 2,000 employees. Olivier Loeillot is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $738M 10-K, 2026-02-26 | $634M 10-K, 2026-02-26 | $632M 10-K, 2026-02-26 | $802M 10-K, 2025-03-14 | $671M 10-K/A, 2024-11-18 |
| Operating income | $55.2M 10-K, 2026-02-26 | -$35.1M 10-K, 2026-02-26 | $47.7M 10-K, 2026-02-26 | $225M 10-K, 2025-03-14 | $167M 10-K/A, 2024-11-18 |
| SG&A | $291M 10-K, 2026-02-26 | $263M 10-K, 2026-02-26 | $219M 10-K, 2026-02-26 | $216M 10-K, 2025-03-14 | $184M 10-K/A, 2024-11-18 |
| Net income | $48.9M 10-K, 2026-02-26 | -$25.5M 10-K, 2026-02-26 | $35.6M 10-K, 2026-02-26 | $186M 10-K, 2025-03-14 | $128M 10-K/A, 2024-11-18 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Olivier Loeillot Chief Executive Officer & Board member at REPLIGEN | Chief Executive Officer | 4, 2026-09-25 |
| Jason K. Garland | CFO | 4, 2026-09-28 |
| Violetta Hughes Chief Accounting Officer @ Repligen | CPA, Financial Reporting | CHIEF ACCOUNTING OFFICER | 4, 2026-09-02 |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 4, 2026-05-08 |
| Brian Douglass | Named in proxy bio: Senior Vice President, CPO | DEF 14A, 2026-04-02 |
| James Bylund Chief Operating Officer | Chief Operating Officer | 4, 2026-03-23 |
| Ralf Kuriyel Sr. Vice President at Repligen | Senior VP, R&D | 4, 2026-03-23 |
| Martin Madaus, D.V.M., Ph.D. | Board member (per proxy) bio: Director, Chair of the Board | DEF 14A, 2026-04-02 |
| Tony J. Hunt | Executive Chair of the Board | 10-K, 2026-02-26 |
| Carrie Eglinton Manner | Director | 10-K, 2026-02-26 |
| Glenn P. Muir | Director | 10-K, 2026-02-26 |
| Karen Dawes | Lead Independent Director | 10-K, 2026-02-26 |
| Konstantin Konstantinov | Director | 10-K, 2026-02-26 |
| Margaret A. Pax | Director | 10-K, 2026-02-26 |
| Martin D. Madaus | Director | 10-K, 2026-02-26 |
| Nicolas M. Barthelemy | Director | 10-K, 2026-02-26 |
What Repligen Corp does
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 63.9 million (as of October 23, 2026) | 10-Q, October 30, 2026 |
|---|---|---|
| Public float | $6.0B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 30, 2026 |
| Latest proxy statement | Meeting May 14, 2026 (filed April 2, 2026) | DEF 14A, April 2, 2026 |
| Auditor | Ernst & Young LLP (Boston, Massachusetts, United States) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 5, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 5,535 | $1.0M | Form 4, October 6, 2026 |
| September 24, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 12,946 | $2.5M | Form 4, September 25, 2026 |
| September 21, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 5,426 | $977K | Form 4, September 22, 2026 |
| September 4, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 3,035 | $504K | Form 4, September 8, 2026 |
| August 20, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 5,426 | $977K | Form 4, August 21, 2026 |
| July 16, 2026 | Jason K. Garland CFO | Sale | 530 | $80K | Form 4, July 17, 2026 |
| June 25, 2026 | Jason K. Garland CFO | Sale | 733 | $106K | Form 4, June 26, 2026 |
| April 21, 2026 | Olivier Loeillot Chief Executive Officer | Sale | 3,832 | $536K | Form 4, April 22, 2026 |
Recent 8-K events
- 8-K filed 2026-11-06
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-10-30
- Item 3.02 Unregistered sales of equity securities
- Item 8.01 Other events
- 8-K filed 2026-10-27
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-06
- Item 2.01 Completion of acquisition or disposition of assets
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-15
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-08
- Item 8.01 Other events
- 8-K filed 2026-07-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-22
- Item 1.01 Entry into a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-05-15
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Repligen Corp
- What does Repligen Corp do?
- In its own words, from Item 1 of its 10-K: "Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs."
- What is Repligen Corp's revenue?
- $738M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Repligen Corp profitable?
- Repligen Corp reported net income of $48.9M for the fiscal year ending December 31, 2025.
- How many employees does Repligen Corp have?
- About 2,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Repligen Corp?
- Olivier Loeillot, Chief Executive Officer, as named in a 4 filed September 25, 2026.
- Who is the CFO of Repligen Corp?
- Jason K. Garland, CFO, as named in a 4 filed September 28, 2026.
- Where is Repligen Corp headquartered?
- Waltham, MA.
- What is Repligen Corp's stock ticker?
- RGEN on Nasdaq.
- What industry is Repligen Corp in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Repligen Corp's website?
- repligen.com.
- When does Repligen Corp report earnings next?
- January 26, 2027. Source: estimate_8k_pattern.
- Is Repligen Corp a public company?
- Yes. Repligen Corp files with the SEC under CIK 0000730272 and trades as RGEN.
- Who audits Repligen Corp?
- Ernst & Young LLP, Boston, Massachusetts, United States, as named in its latest annual report (10-K).
- How many shares of Repligen Corp are outstanding?
- 63.9 million shares as of October 23, 2026, from its 10-Q filed October 30, 2026.
- What is Repligen Corp's public float?
- $6.0B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Repligen Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 30, 2026.
- When is Repligen Corp's annual shareholder meeting?
- May 14, 2026, per its proxy statement (DEF 14A) filed April 2, 2026.
- Have Repligen Corp insiders traded stock recently?
- Since August 8, 2025, officers and directors reported 14 open-market sales worth about $18.8M and 1 purchase worth about $202K on Forms 4 and 5. The most recent: Olivier Loeillot (Chief Executive Officer) sold 5,535 shares on October 5, 2026.